menu
    • menu
    [{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"AS03","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Innovax Biotech \/ Xiamen Innovax Biotech","highestDevelopmentStatusID":"1","companyTruncated":"Xiamen Innovax Biotech \/ Xiamen Innovax Biotech"},{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"Xiamen Innovax Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"Human Papillomavirus 9-valent Vaccine, Recombinant","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase III","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Xiamen Innovax Biotech \/ Xiamen Innovax Biotech","highestDevelopmentStatusID":"10","companyTruncated":"Xiamen Innovax Biotech \/ Xiamen Innovax Biotech"},{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Human Papillomavirus Vaccine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Innovax Biotech \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Innovax Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"Center for Disease Control and Prevention, Fujian","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Recombinant Hepatitis E Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Innovax Biotech \/ Center for Disease Control and Prevention, Fujian","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Innovax Biotech \/ Center for Disease Control and Prevention, Fujian"},{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"Jiangsu Province Centers for Disease Control and Prevention | Dongtai City Centers for Disease Control and Prevention","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Pill","sponsorNew":"Xiamen Innovax Biotech \/ Jiangsu Province Centers for Disease Control and Prevention | Dongtai City Centers for Disease Control and Prevention","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Innovax Biotech \/ Jiangsu Province Centers for Disease Control and Prevention | Dongtai City Centers for Disease Control and Prevention"},{"orgOrder":0,"company":"Xiamen Innovax Biotech","sponsor":"Zhejiang Provincial CDC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"Bivalent Hpv Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Xiamen Innovax Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xiamen Innovax Biotech \/ Zhejiang Provincial CDC","highestDevelopmentStatusID":"11","companyTruncated":"Xiamen Innovax Biotech \/ Zhejiang Provincial CDC"}]

    Find Clinical Drug Pipeline Developments & Deals by Xiamen Innovax Biotech

    Menu

    Xiamen Innovax Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : Xiamen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-...

                            Details : Human Papillomavirus 9-valent Vaccine, Recombinant is a Vaccine drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Perianal Intraepithelial Neoplasia.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            March 10, 2025

                            Lead Product(s) : Human Papillomavirus 9-valent Vaccine, Recombinant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : Xiamen University

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Center for Disease Control and Prevention, Fujian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Immunogenicity Study of Thiomersal-free Hepatitis E Vaccine in People Ages 16 Years and Above

                            Details : Recombinant Hepatitis E Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis E.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            August 21, 2024

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Center for Disease Control and Prevention, Fujian

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of One Dose of HPV Vaccine

                            Details : Human Papillomavirus Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            April 03, 2024

                            Lead Product(s) : Human Papillomavirus Vaccine

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase IV

                            Sponsor : Jiangsu Province Centers for Disease Control and Prevention | Dongtai City Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female

                            Details : Cecolin (Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Uterine Cervical Dysplasia.

                            Product Name : Cecolin

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 21, 2022

                            Lead Product(s) : Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase IV

                            Sponsor : Jiangsu Province Centers for Disease Control and Prevention | Dongtai City Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine,Bivalent Hpv Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Zhejiang Provincial CDC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Immunogenicity and Safety of Co-immunization With Cecolin and Hecolin

                            Details : Cecolin (Bivalent Hpv Vaccine) is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Papillomavirus Infections.

                            Product Name : Cecolin

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            June 13, 2022

                            Lead Product(s) : Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine,Bivalent Hpv Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Zhejiang Provincial CDC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AS03,Recombinant protein-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : GSK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            GSK allies with Innovax for COVID-19 vaccine R&D project

                            Details : The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 03, 2020

                            Lead Product(s) : AS03,Recombinant protein-Based Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : GSK

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Jiangsu Province Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase â…£ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency T...

                            Details : Recombinant Hepatitis E Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis E.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            December 07, 2017

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Jiangsu Province Centers for Disease Control and Prevention

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)

                            Details : Recombinant Hepatitis E Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis E.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            May 30, 2017

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase â…£ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis...

                            Details : Recombinant Hepatitis E Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis E.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            November 16, 2016

                            Lead Product(s) : Recombinant Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed

                            Xiamen Innovax Biotech

                            China arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase â…£ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With...

                            Details : Hepatitis E Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hepatitis E.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            October 22, 2015

                            Lead Product(s) : Hepatitis E Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth